Kielstein Jan T, Bode-Böger Stefanie M, Frölich Jürgen C, Ritz Eberhard, Haller Hermann, Fliser Danilo
Department of Internal Medicine, Medical School Hannover, Germany.
Circulation. 2003 Apr 15;107(14):1891-5. doi: 10.1161/01.CIR.0000060496.23144.A7. Epub 2003 Apr 7.
Reduced availability of nitric oxide (NO) is thought to contribute to the age-associated increase of renovascular tone and blood pressure. We assessed blood concentrations of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) as well as renal hemodynamics, comparing young (n=24, 13 men, 25+/-1 years) and elderly (n=24, 13 men, 69+/-2 years) healthy subjects and elderly subjects with essential hypertension (n=24, 13 men, 70+/-2 years).
Plasma ADMA concentration and renovascular resistance (RVR) were significantly higher (P<0.05) and effective renal plasma flow (ERPF) significantly lower (P<0.05) in elderly (2.77+/-0.20 micromol/L, 125+/-10 mm Hg/mL per minute, 487+/-26 mL/min per 1.73 m2) than in young healthy subjects (1.30+/-0.11, 77+/-3, 654+/-18). Both ADMA levels and RVR were higher and ERPF lower in the hypertensive elderly subjects (3.53+/-0.23, 163+/-11, 427+/-19; P<0.05 versus both groups). In contrast, plasma concentrations of the biologically inactive stereoisomer symmetric dimethylarginine, l-arginine, and homocysteine were similar in the 3 groups studied. In the logistic regression analysis only ADMA was an independent determinant of both ERPF (P<0.001; r2=0.80) and RVR (P<0.002; r2=0.86). In addition, ADMA (P<0.002) and serum glucose (P<0.036) were independently related (r2=0.67) to the level of blood pressure.
These results are compatible with the notion that accumulation of the endogenous NO synthase inhibitor ADMA in senescent individuals is involved in the decrease of renal perfusion and increase of blood pressure.
一氧化氮(NO)可用性降低被认为与肾血管张力和血压随年龄增长而升高有关。我们比较了年轻(n = 24,男性13名,25±1岁)和老年(n = 24,男性13名,69±2岁)健康受试者以及老年原发性高血压患者(n = 24,男性13名,70±2岁)的内源性NO合酶抑制剂不对称二甲基精氨酸(ADMA)的血浓度以及肾血流动力学。
老年受试者(2.77±0.20 μmol/L,125±10 mmHg/mL每分钟,487±26 mL/min每1.73 m²)的血浆ADMA浓度和肾血管阻力(RVR)显著更高(P<0.05),有效肾血浆流量(ERPF)显著更低(P<0.05),高于年轻健康受试者(1.30±0.11,77±3,654±18)。高血压老年受试者的ADMA水平和RVR更高,ERPF更低(3.53±0.23,163±11,427±19;与两组相比P<0.05)。相比之下,所研究的3组中生物活性无的立体异构体对称二甲基精氨酸、L-精氨酸和同型半胱氨酸的血浆浓度相似。在逻辑回归分析中,只有ADMA是ERPF(P<0.001;r² = 0.80)和RVR(P<0.002;r² = 0.86)的独立决定因素。此外,ADMA(P<0.002)和血糖(P<0.036)与血压水平独立相关(r² = 0.67)。
这些结果与内源性NO合酶抑制剂ADMA在衰老个体中的蓄积参与肾灌注降低和血压升高这一观点相符。